Registered title, quoted from ClinicalTrials.gov
A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography
An open trial on congenital heart disease, registered on ClinicalTrials.gov. Led by First Hospital of China Medical University; 11 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 12
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
- Study siteAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page
- Study siteBeijing Chao-Yang Hospital首都医科大学附属北京朝阳医院BeijingHospital page
- Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
- Study siteHenan Provincial People's Hospital河南省人民医院ZhengzhouHospital page
- Study siteSecond Hospital of Jilin University吉林大学第二医院ChangchunHospital page
- Study siteShanghai Chest Hospital上海市胸科医院ShanghaiHospital page
- Study siteShanxi Provincial People's Hospital山西省人民医院TaiyuanHospital page
- Study siteShenzhen People's Hospital深圳市人民医院ShenzhenHospital page
- Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
- Study siteWest China Hospital四川大学华西医院ChengduHospital page
- Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07292896, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 3
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (3 points)Hide the checklist
18 years to 79 years; sex: all
Registered eligibility fields
Normal liver and renal function (alanine transaminase < 2× upper limit of normal; normal creatinine and blood urea nitrogen)
Inclusion criterion 8
Abnormal liver function (alanine transaminase > 2× upper limit of normal), abnormal renal function (elevated creatinine beyond normal range), or dyslipidemia (elevated triglycerides, total cholesterol, low-density lipoprotein, or high-density lipoprotein)
Exclusion criterion 4
Pregnant or lactating women
Exclusion criterion 6
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07292896, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Healthy Adults Group
Inclusion Criteria:
- Participants must meet all of the following criteria to be enrolled:
- Of Han Chinese ethnicity
- Aged 18-79 years
- Normal blood pressure (< 140/90 mmHg)
- Normal fasting blood glucose
- Normal blood lipid levels (triglycerides, total cholesterol, low-density lipoprotein, high-density lipoprotein)
- Normal complete blood count results (hemoglobin concentration, white blood cell count, red blood cell count, platelet count)
- Normal liver and renal function (alanine transaminase < 2× upper limit of normal; normal creatinine and blood urea nitrogen)
- Normal electrocardiogram results (occasional atrial premature beats may be enrolled at the investigator's discretion)
- No structural heart disease and normal cardiac function confirmed by echocardiography
Exclusion Criteria:
Participants will be excluded if they meet any of the following criteria:
- Clinically significant cardiac valve regurgitation (≥ mild severity)
- Respiratory diseases: acute or chronic respiratory disorders
- Endocrine diseases: thyroid disease, diabetes mellitus, hyperaldosteronism, pheochromocytoma, etc.
- Abnormal liver function (alanine transaminase > 2× upper limit of normal), abnormal renal function (elevated creatinine beyond normal range), or dyslipidemia (elevated triglycerides, total cholesterol, low-density lipoprotein, or high-density lipoprotein)
- Other systemic diseases: anemia, malignancy, connective tissue disease, large artery/peripheral vascular diseases (aortic dilation, aortic dissection, coarctation of the aorta, Takayasu arteritis, atherosclerosis), etc.
- Pregnant or lactating women
- Professional athletes
- Poor-quality ultrasound images that cannot support parameter measurement and analysis
Pulmonary Hypertension Group
Inclusion Criteria:
Patients must meet all of the following criteria to be enrolled:
- Aged 18-79 years
- Confirmed diagnosis via right heart catheterization: mean pulmonary arterial pressure (mPAP) ≥ 20 mmHg, in accordance with the 2022 ESC/ERS guidelines
Exclusion Criteria:
Patients will be excluded if they meet any of the following criteria:
- Unable to complete right heart catheterization or pressure-volume loop assessment
- Complicated with significant left heart disease (left ventricular ejection fraction [LVEF] < 50%, significant mitral valve disease)
- Pericardial disease or arrhythmias (e.g., atrial fibrillation) that severely impair right heart function evaluation
- Poor-quality images that prevent accurate measurement of right atrial or right ventricular parameters
- Concurrent liver or renal disease
- Concurrent malignancy
- History of surgical procedures such as pulmonary endarterectomy or balloon pulmonary angioplasty
Heart Failure Group
Inclusion Criteria:
Patients must meet all of the following criteria to be enrolled:
- Aged 18-79 years
- Meets the 2022 AHA/ACC/HFSA diagnostic criteria for heart failure
Exclusion Criteria:
Patients will be excluded if they meet any of the following criteria:
1.Complicated with significant valvular heart disease (e.g., severe mitral regurgitation, severe tricuspid regurgitation, etc.)
Tricuspid Regurgitation Group
Inclusion Criteria:
Patients must meet all of the following criteria to be enrolled:
- Moderate or severe primary or secondary tricuspid regurgitation confirmed by echocardiography
- Aged 18-79 years
Exclusion Criteria:
Patients will be excluded if they meet any of the following criteria:
- Pericardial disease or arrhythmias (persistent atrial fibrillation) that interfere with measurements
- Congenital heart disease or residual lesions after surgical correction
Atrial Septal Defect Group
Inclusion Criteria:
Patients must meet all of the following criteria to be enrolled:
- Secundum atrial septal defect confirmed by echocardiography or transesophageal echocardiography
- Patients who have not undergone closure or surgical correction, or stable patients with > 3 months postoperatively
- Aged 18-79 years
Exclusion Criteria:
1.Complicated with other complex congenital heart diseases.
Quoted from ClinicalTrials.gov, NCT07292896, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07292896, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.